For research use only. Not for therapeutic Use.
LUF6283 is a potent and orally active HCA(2) partial agonist, with a Ki of 0.55 µM. LUF6283 can achieve the beneficial lipid lowering effect of niacin without producing the unwanted cutaneous flushing side effect[1].
LUF6283 (C57BL/6 mice, 400 mg/kg, Oral gavage, once a day for 4 weeks) has no effect on adipose tissue ATGL/HSL expression, and significantly reduces the expression of apolipoprotein B (APOB)[1].
Catalog Number | I011047 |
CAS Number | 92933-48-7 |
Synonyms | 5-butyl-1H-pyrazole-3-carboxylic acid |
Molecular Formula | C8H12N2O2 |
Purity | ≥95% |
InChI | InChI=1S/C8H12N2O2/c1-2-3-4-6-5-7(8(11)12)10-9-6/h5H,2-4H2,1H3,(H,9,10)(H,11,12) |
InChIKey | ZJTXSGLJNBAMJS-UHFFFAOYSA-N |
SMILES | CCCCC1=CC(=NN1)C(=O)O |
Reference | [1]. Li Z, et al. Effects of pyrazole partial agonists on HCA(2) -mediated flushing and VLDL-triglyceride levels in mice. Br J Pharmacol. 2012 Oct;167(4):818-25. |